|
Imaging Probe Development Center (IPDC)
|
NHL12016-001-01163
|
$1,529,042
|
N/A
|
NHLBI-NATIONAL HEART, LUNG, AN
|
|
Research Management and Support
|
RMS ES 2018
|
$340,640,887
|
N/A
|
National Institutes of Health
|
|
IGF::OT::IGF
|
261201800038C
|
$1,499,993
|
-, -
|
INTELLIGENT AUTOMATION, INC.
|
|
Modeling bladder cancer pathogenesis and tumor evolution
|
1P01CA221757-01A1
|
$1,765,498
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Development of personalized surgical algorithms for muscle-invasive bladder cancer patients
|
5R21CA218976-02
|
$238,815
|
ABBOSH, PHILIP
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
Quantitative MRI for Predicting Response of Breast Cancer to Neoadjuvant Therapy
|
5U01CA142565-10
|
$461,172
|
ABRAMSON, RICHARD
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
Center for Multiple Myeloma Nanotherapy
|
5U54CA199092-04
|
$2,184,301
|
ACHILEFU, SAMUEL
|
WASHINGTON UNIVERSITY
|
|
NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 Emphasis
|
5UM1CA186686-04
|
$1,900,619
|
ADJEI, ALEX
|
MAYO CLINIC ROCHESTER
|
|
Identifying the Drivers and Targeting Chemo Resistance in Ovarian Cancer
|
5R01CA211648-02
|
$432,788
|
ADLI, MAZHAR
|
UNIVERSITY OF VIRGINIA
|
|
Plumbagin in Combination with Vemurafenib for BRAF-mutant Melanoma
|
5R03CA212798-02
|
$74,250
|
AFAQ, FARRUKH
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Novel Combinatorial Therapeutic Approach for Prostate Cancer
|
5R03CA219336-02
|
$74,250
|
AFAQ, FARRUKH
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Skin Cancer Chemoprevention by Silibinin: Mechanisms and Efficacy
|
5R01CA140368-07
|
$369,313
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
|
Targeting SHP2 as a precision medicine for the treatment of HER2-positive breast cancer
|
1R01CA213996-01A1
|
$343,125
|
AGAZIE, YEHENEW
|
WEST VIRGINIA UNIVERSITY
|
|
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation
|
4R44CA203336-02
|
$659,516
|
AGUILAR-CORDOVA, ESTUARDO
|
ADVANTAGENE, INC
|
|
Assessment of sensory gating, attention, and executive control in breast cancer
|
1R01CA218496-01A1
|
$687,576
|
AHLES, TIM
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
CCNY-MSKCC Partnership for Cancer Research Training & Community Outreach (1 of 2
|
3U54CA137788-10S1
|
$54,859
|
AHLES, TIM
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
CCNY-MSKCC Partnership for Cancer Research Training & Community Outreach (1 of 2
|
3U54CA137788-10S2
|
$188,884
|
AHLES, TIM
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Mapping cancer micro-environments for acute leukemia
|
5R01CA202025-03
|
$455,870
|
AIFANTIS, IANNIS
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
Title: Pre-clinical Evaluation of a Novel Immune Modulator, Alpha-TEA in Combination with Immune Checkpoint Blockade
|
1R43CA228721-01
|
$299,607
|
AKPORIAYE, EMMANUEL
|
VEANA THERAPEUTICS, LLC
|
|
Targeting transducin Beta-like protein 1 in mantle cell lymphoma
|
1K08CA226352-01
|
$227,046
|
ALINARI, LAPO
|
OHIO STATE UNIVERSITY
|
|
Hyperbaric oxygen to improve blood count recovery in Auto-HCT for myeloma
|
1R37CA225791-01
|
$358,389
|
ALJITAWI, OMAR
|
UNIVERSITY OF ROCHESTER
|
|
Targeting Tumor Initiating Cell in Undifferentiated Pleomorphic Sarcoma
|
5R01CA183811-05
|
$435,560
|
ALMAN, BENJAMIN
|
DUKE UNIVERSITY
|
|
Therapeutic resistance in leukemic cells: targeting BCL-2 family and autophagy
|
5R01CA184137-04
|
$362,569
|
ALMASAN, ALEXANDRU
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Multi-Tensor Decompositions for Personalized Cancer Diagnostics and Prognostics
|
5U01CA202144-04
|
$741,952
|
ALTER, ORLY
|
UNIVERSITY OF UTAH
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-49S1
|
$142,498
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-49S2
|
$200,000
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
5P30CA010815-49
|
$2,645,581
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Novel Markers for Disease Outcome in Breast Cancer
|
ZIA BC 010887
|
$399,760
|
Ambs, Stefan
|
CCR (NCI)
|
|
Novel Dual Notch/PXR Targeting for Colon Cancer Therapy
|
5R01CA182872-05
|
$661,842
|
ANANT, SHRIKANT
|
UNIVERSITY OF KANSAS MEDICAL CENTER
|
|
Sensitization to CD47 Blockade to Enhance Anti-Tumor Immunity
|
5F30CA195973-04
|
$49,524
|
ANDERSON, KATIE
|
UNIVERSITY OF MINNESOTA
|
|
Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications
|
5R01CA050947-26
|
$301,545
|
ANDERSON, KENNETH
|
DANA-FARBER CANCER INST
|
|
Clinical trials in women's cancers
|
ZIA BC 011584
|
$192,282
|
Annunziata, Christina
|
CCR (NCI)
|
|
Targeting the MET pathway in urothelial carcinoma
|
ZIA BC 011594
|
$497,661
|
Apolo, Andrea
|
CCR (NCI)
|
|
PQ2 Obesity-induced fibrocytes promote breast cancer progression
|
1R01CA227542-01
|
$349,988
|
ARENDT, LISA
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
Targeting DOT1L for Degradation in MLL-rearranged Leukemia
|
2R01CA176745-07
|
$404,076
|
ARMSTRONG, SCOTT
|
DANA-FARBER CANCER INST
|
|
Childhood Cancer Survivor Study
|
3U24CA055727-24S1
|
$120,439
|
ARMSTRONG, GREGORY
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Childhood Cancer Survivor Study
|
5U24CA055727-24
|
$4,218,764
|
ARMSTRONG, GREGORY
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Stanford Cancer Institute
|
3P30CA124435-11S1
|
$248,520
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
Stanford Cancer Institute
|
3P30CA124435-11S2
|
$171,518
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
Stanford Cancer Institute
|
5P30CA124435-11
|
$3,334,464
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
Role of HER2 mutations in breast cancer progression and response to targeted therapies
|
1R01CA224899-01A1
|
$382,641
|
ARTEAGA, CARLOS
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Cancer Center Support Grant - UT Southwestern Medical Center
|
3P30CA142543-09S1
|
$249,371
|
ARTEAGA, CARLOS
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Cancer Center Support Grant - UT Southwestern Medical Center
|
5P30CA142543-09
|
$2,480,000
|
ARTEAGA, CARLOS
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Dual Targeting Redox?active Gold(I) Therapeutics
|
1R15CA232765-01
|
$462,195
|
ARUMUGAM, KUPPUSWAMY
|
WRIGHT STATE UNIVERSITY
|
|
Cancer Center Support Grant
|
2P30CA082103-19
|
$7,954,381
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-19S1
|
$84,000
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-19S2
|
$206,488
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-19S3
|
$257,838
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
A Prospective Study of the Impact of Breast Cancer on Symptoms and Functioning
|
5R01CA199137-04
|
$55,401
|
AVIS, NANCY
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
|
Reducing Cancer Transcriptional Heterogeneity through Regulation of Chromatin Structure
|
1R01CA228272-01
|
$659,504
|
BACKMAN, VADIM
|
NORTHWESTERN UNIVERSITY
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|